Alain M Monnier
- The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98A Monnier
Centre Hospitalier Belfort Montbeliard, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
Breast 15:S21-9. 2006..81; P=0.003), especially reducing distant metastases (hazard ratio 0.73; P=0.0012). These results establish letrozole as part of standard adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer...
- Adjuvant trials: Aromatase inhibitors in early breast cancer--are they alike?Alain Monnier
Head of Medical Oncology, Centre Hospitalier Belfort Montbeliard, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
Cancer Treat Rev 32:532-40. 2006..Results of trials currently under way should determine the optimal use of the aromatase inhibitors in breast cancer therapy...
- Refining the postmenopausal breast cancer treatment paradigm: the FACE trialAlain Monnier
Centre Hospitalier Belfort Montbeliard, 25206 Montbeliard Cedex, France
Expert Rev Anticancer Ther 6:1355-9. 2006..The results are expected to further refine the treatment paradigm for breast cancer in postmenopausal patients with node-positive disease...
- Effects of adjuvant aromatase inhibitor therapy on lipid profilesAlain Monnier
Centre Hospitalier A Boulloche, Oncology Medical Department, 1 Rue du docteur flamand, 25209 Montbeliard Cedex, France
Expert Rev Anticancer Ther 6:1653-62. 2006..This review discusses the current understanding of the influence of lipid levels on cardiovascular risk in women and presents key findings on the effects of adjuvant aromatase inhibitor therapy on lipid profiles...
- The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancerAlain M Monnier
Department of Medical Oncology, Centre Hospitalier A Boulloche, Montbeliard Cedex, France
Expert Rev Anticancer Ther 7:627-34. 2007..e., anastrozole or letrozole) and information as to the optimal treatment strategy (i.e., initial adjuvant aromatase inhibitor therapy or sequential adjuvant aromatase inhibitor therapy)...
- Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancerA Monnier
Centre Hospitalier Belfort Montbeliard, Montbeliard, France
Ann Oncol 18:viii36-44. 2007....